Halozyme Therapeutics Inc (HALO)
Financial leverage ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | US$ in thousands | 2,063,480 | 2,118,030 | 1,969,450 | 1,841,530 | 1,733,270 | 1,892,660 | 1,810,440 | 1,699,450 | 1,841,510 | 1,864,540 | 1,781,390 | 1,162,250 | 1,104,430 | 1,185,420 | 1,025,860 | 966,582 | 579,924 | 524,029 | 526,997 | 492,353 |
| Total stockholders’ equity | US$ in thousands | 363,821 | 452,703 | 289,424 | 177,808 | 83,808 | 249,181 | 151,033 | 65,850 | 169,798 | 96,991 | 293,171 | 260,256 | 196,953 | 281,674 | 119,748 | 67,595 | 151,047 | 98,988 | 105,577 | 58,042 |
| Financial leverage ratio | 5.67 | 4.68 | 6.80 | 10.36 | 20.68 | 7.60 | 11.99 | 25.81 | 10.85 | 19.22 | 6.08 | 4.47 | 5.61 | 4.21 | 8.57 | 14.30 | 3.84 | 5.29 | 4.99 | 8.48 |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $2,063,480K ÷ $363,821K
= 5.67
The financial leverage ratio of Halozyme Therapeutics Inc has shown fluctuations over the years, indicating changes in the company's debt levels relative to its equity. The ratio was relatively high in the first quarter of 2020 at 8.48, signifying higher financial leverage at that time. There was a notable decrease in the ratio by the end of the year, reaching 3.84 by December 31, 2020, indicating a lower reliance on debt financing.
Subsequently, the financial leverage ratio experienced some volatility throughout 2021 and 2022, fluctuating between 4.21 and 25.81. These fluctuations suggest varying levels of debt utilization by the company during this period. Notably, the ratio peaked at 25.81 by March 31, 2023, indicating a significant increase in financial leverage at that point.
From 2023 to 2024, the financial leverage ratio started to decline gradually, ranging between 4.68 and 10.36 by the end of December 31, 2024. This trend may suggest the company's efforts to manage and reduce its debt levels during this period.
Overall, the analysis of Halozyme Therapeutics Inc's financial leverage ratio highlights fluctuations in the company's debt-to-equity structure over the years, showcasing periods of higher and lower financial leverage. Investors and stakeholders should closely monitor these changes to assess the company's risk profile and financial stability.
Peer comparison
Dec 31, 2024